Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

SULF2 expression by immunohistochemistry and overall survival in oesophageal cancer: a cohort study.

Lui NS, van Zante A, Rosen SD, Jablons DM, Lemjabbar-Alaoui H.

BMJ Open. 2012 Nov 23;2(6). pii: e001624. doi: 10.1136/bmjopen-2012-001624. Print 2012.

2.

SULF2 Expression Is a Potential Diagnostic and Prognostic Marker in Lung Cancer.

Lui NS, Yang YW, van Zante A, Buchanan P, Jablons DM, Lemjabbar-Alaoui H.

PLoS One. 2016 Feb 16;11(2):e0148911. doi: 10.1371/journal.pone.0148911. eCollection 2016.

3.

Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer.

Lim SH, Hong M, Ahn S, Choi YL, Kim KM, Oh D, Ahn YC, Jung SH, Ahn MJ, Park K, Zo JI, Shim YM, Sun JM.

Eur J Cancer. 2016 Jan;52:1-9. doi: 10.1016/j.ejca.2015.09.019. Epub 2015 Nov 26.

PMID:
26623522
4.

Comparison of survival among neoadjuvant chemoradiation responders, non-responders and patients receiving primary resection for locally advanced oesophageal squamous cell carcinoma: does neoadjuvant chemoradiation benefit all?

Hsu PK, Chien LI, Huang CS, Hsieh CC, Wu YC, Hsu WH, Chou TY.

Interact Cardiovasc Thorac Surg. 2013 Sep;17(3):460-6. doi: 10.1093/icvts/ivt216. Epub 2013 May 31.

5.

[Surgery of esophageal cancer in Liège. II. Analysis of factors influencing long-term survival after esophagectomy for epidermoid cancer or adenocarcinoma].

Kolh P, Honoré P, Degauque C, Azzam C, Gielen JL, Legrand M, Dewé W, Jacquet N.

Rev Med Liege. 1998 Jun;53(6):363-9. French.

PMID:
9713218
6.

Prognostic impact of neoadjuvant chemoradiation in cT3 oesophageal cancer - A propensity score matched analysis.

Hölscher AH, Bollschweiler E, Bogoevski D, Schmidt H, Semrau R, Izbicki JR.

Eur J Cancer. 2014 Nov;50(17):2950-7. doi: 10.1016/j.ejca.2014.08.020. Epub 2014 Oct 9.

PMID:
25307749
7.

Non-surgical versus surgical treatment for oesophageal cancer.

Best LM, Mughal M, Gurusamy KS.

Cochrane Database Syst Rev. 2016 Mar 29;3:CD011498. doi: 10.1002/14651858.CD011498.pub2. Review.

PMID:
27021481
8.

Overexpression of G9a and MCM7 in oesophageal squamous cell carcinoma is associated with poor prognosis.

Zhong X, Chen X, Guan X, Zhang H, Ma Y, Zhang S, Wang E, Zhang L, Han Y.

Histopathology. 2015 Jan;66(2):192-200. doi: 10.1111/his.12456. Epub 2014 Nov 13.

PMID:
24805087
9.

Prognostic value of nuclear survivin expression in oesophageal squamous cell carcinoma.

Grabowski P, Kühnel T, Mühr-Wilkenshoff F, Heine B, Stein H, Höpfner M, Germer CT, Scherübl H.

Br J Cancer. 2003 Jan 13;88(1):115-9.

10.

Expression of the extracellular sulfatase SULF2 is associated with squamous cell carcinoma of the head and neck.

Flowers SA, Zhou X, Wu J, Wang Y, Makambi K, Kallakury BV, Singer MS, Rosen SD, Davidson B, Goldman R.

Oncotarget. 2016 Jul 12;7(28):43177-43187. doi: 10.18632/oncotarget.9506.

11.

Correlation between cathepsin D expression and p53 protein nuclear accumulation in oesophageal squamous cell carcinoma.

Ikeguchi M, Sakatani T, Ueta T, Fukuda K, Oka S, Hisamitsu K, Yamaguchi K, Tsujitani S, Kaibara N.

J Clin Pathol. 2002 Feb;55(2):121-6.

12.

Can metformin improve 'the tomorrow' of patients treated for oesophageal cancer?

Van De Voorde L, Janssen L, Larue R, Houben R, Buijsen J, Sosef M, Vanneste B, Schraepen MC, Berbée M, Lambin P.

Eur J Surg Oncol. 2015 Oct;41(10):1333-9. doi: 10.1016/j.ejso.2015.05.012. Epub 2015 Jun 6.

PMID:
26091848
13.

Circumferential resection margin involvement: an independent predictor of survival following surgery for oesophageal cancer.

Dexter SP, Sue-Ling H, McMahon MJ, Quirke P, Mapstone N, Martin IG.

Gut. 2001 May;48(5):667-70.

14.

Prognostic influence of immunohistochemically detected lymph node micrometastasis and histological subtype in pN0 oesophageal cancer.

Zingg U, Montani M, Busch M, Metzger U, Went P, Oertli D.

Eur J Surg Oncol. 2009 Jun;35(6):593-9. doi: 10.1016/j.ejso.2008.12.001. Epub 2009 Jan 3.

PMID:
19121916
15.

Association of syndecan-1 with tumor grade and histology in primary invasive cervical carcinoma.

Rintala M, Inki P, Klemi P, Jalkanen M, Grénman S.

Gynecol Oncol. 1999 Dec;75(3):372-8.

PMID:
10600292
16.

Treatment strategies for oesophageal cancer - time-trends and long term outcome data from a large tertiary referral centre.

Wolf MC, Zehentmayr F, Schmidt M, Hölzel D, Belka C.

Radiat Oncol. 2012 Apr 15;7:60. doi: 10.1186/1748-717X-7-60.

17.

Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis.

Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, Gebski V; Australasian Gastro-Intestinal Trials Group.

Lancet Oncol. 2011 Jul;12(7):681-92. doi: 10.1016/S1470-2045(11)70142-5. Epub 2011 Jun 16.

PMID:
21684205
18.

Induction chemotherapy followed by surgery for advanced oesophageal cancer.

Toxopeus EL, Talman S, van der Gaast A, Spaander VM, van Rij CM, Krak NC, Biermann K, Tilanus HW, Mathijssen RH, van Lanschot JJ, Wijnhoven BP.

Eur J Surg Oncol. 2015 Mar;41(3):323-32. doi: 10.1016/j.ejso.2014.11.043. Epub 2014 Dec 3.

PMID:
25534280
19.

Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin.

Wu X, Wanders A, Wardega P, Tinge B, Gedda L, Bergstrom S, Sooman L, Gullbo J, Bergqvist M, Hesselius P, Lennartsson J, Ekman S.

Br J Cancer. 2009 Jan 27;100(2):334-43. doi: 10.1038/sj.bjc.6604855. Epub 2009 Jan 13.

20.

SULF2 methylation is prognostic for lung cancer survival and increases sensitivity to topoisomerase-I inhibitors via induction of ISG15.

Tessema M, Yingling CM, Thomas CL, Klinge DM, Bernauer AM, Liu Y, Dacic S, Siegfried JM, Dahlberg SE, Schiller JH, Belinsky SA.

Oncogene. 2012 Sep 13;31(37):4107-16. doi: 10.1038/onc.2011.577. Epub 2011 Dec 12.

Supplemental Content

Support Center